Larimar Therapeutics Inc

NASDAQ:LRMRUnited States

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Contact Information

Headquarters

THREE BALA PLAZA EAST. SUITE 506BALA CYNWYD, PA, United States 19004

Phone

617-622-4003

Fax

302-655-5049

Executives

Independent Chairman of the Board

Joseph Truitt

President, Chief Executive Officer, Director

Carole Ben-Maimon

Chief Financial Officer, Company Secretary

Michael Celano

Chief Medical Officer

Russell Clayton

Chief Development Officer

Gopi Shankar